Hospital Stocks Soared as Democrats Took Congress
HCA posted its biggest one-day jump in four years before a single law changed. Wall Street is pricing in relief that needs Congress, a presidential signature, and a December funding fight to survive. Who is betting on what?
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
HCA Healthcare (NYSE:HCA | HCA Price Prediction) rose 10.34% to close at $510.70 on November 4, 2026. That added $47.84 a share, its biggest one-day gain since an 11.43% jump on July 22, 2022.
The move followed the November 3 election. As of the afternoon of November 4, projections showed Democrats winning at least 237 House seats and at least 54 Senate seats. Alaska and Mississippi were still undecided.
No policy has changed. The new Congress has not been sworn in, and President Trump can still veto anything it passes.
HCA is now worth $106.68 billion. The stock rose. It was buoyed by hopes that Democrats will bring back the enhanced Affordable Care Act (ACA) subsidies and slow the Medicaid cuts in the One Big Beautiful Bill Act (OBBBA). At this price, the stock shows relief that so far exists only in analyst models.
e
Hospitals and Medicaid Insurers Rallied Together
Universal Health Services (NYSE:UHS) rose 10.91%. Tenet Healthcare (NYSE:THC) gained 9.58% to $292.25 after reaching an intraday 52-week high of $294.11.
Centene (NYSE:CNC), an insurance company focused on Medicaid and ACA plans, rose 12.64% to $76.01 after an intraday high of $77.05. Oscar Health (NYSE:OSCR) gained 8.58% and reports third-quarter results before the market opens on November 5.
Why Coverage Losses Cost Hospitals Money
Uninsured patients still come to emergency rooms, but hospitals collect far less from them. HCA said patients who lost exchange coverage after the subsidies ended went almost one-for-one into uninsured status.
HCA’s exchange admissions fell about 19% in the third quarter. The shift in payer mix cut adjusted EBITDA, a measure of operating profit, by roughly $400 million. Centene’s Marketplace membership fell from 5.63 million in the first quarter of 2025 to 3.49 million in the second quarter of 2026.
Bernstein analysts said delays to OBBBA could ease the enrollment losses hospitals expect, and that planned cuts to state-directed payments could be pushed back and possibly avoided completely.
Medicaid Deadlines Still Stand on the Calendar
States must have Medicaid work requirements in place, or get an exception, by January 1, 2027. Provider taxes start on October 1, 2027, and state-directed payments start on January 1, 2028.
Congress will likely need a short-term funding bill in December. Open enrollment ends January 15, 2027, in most states, and ACA benchmark premiums are set to rise an average of 13% for 2027.
Veto Risk and Valuation Cap the Upside
J.P. Morgan analysts expect gridlock, because a Trump veto would likely block any major healthcare change. Trump does not want to veto everything. He has said he does not want to spend two years doing so, and Jefferies analysts saw that as room for some Democratic priorities to pass.
Delaying OBBBA would also cost money. HCA’s own long-term outlook assumes “no material policy changes beyond HR 1.”
The rally also went past where analysts value these stocks. Average price targets are $475.45 for HCA, $192.41 for Universal Health, and $74.50 for Centene, and all three closed above those levels on November 4.
What Could Move HCA Stock Next
At $510.70, HCA’s rally assumes subsidy relief that still needs new legislation and a presidential signature. Exchange losses will keep hurting its 2027 payer mix. HCA also expects $550 million to $650 million less in Medicaid supplemental payments that year.
Centene’s setup looks different, even though it also trades above its average target. The company raised its 2026 adjusted EPS guidance to more than $5.20 and expects growth in 2027 from Medicaid rate increases and better Marketplace margins. That means a subsidy extension would add to a recovery that has already started.
Watch the December funding bill. If it does not extend the enhanced subsidies, HCA would likely slip back toward its $475.45 average target.
Contact [email protected] for any questions or corrections.
Omor Ibne Ehsan is a writer at 24/7 Wall St. He is a self-taught investor with a focus on growth, cyclical, and dividend equities that have strong fundamentals, value, and long-term potential. He also has an interest in high-risk, high-reward investments such as penny stocks.
